Shares of MetaVia Inc. (MTVA) slipped over 24% on Tuesday morning after the clinical-stage biotechnology company reported positive trial results of obesity drug.
MTVA is currently trading at $1.3903, down $0.4497 or 24.4402%, on a heavy volume of 20.2 million shares, above average volume of 30 thousand, on the Nasdaq. The stock opened its trading at $1.9700 after closing Monday at $1.8400. The stock has traded between $1.2600 and $5.3000 in the past 52-week period.
MetaVia announced positive results from the 4-week multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
In the 28-day, 36-subject MAD portion of the study, DA-1726 demonstrated excellent safety and tolerability, with positive clinical activity.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.